Curis Inc
NASDAQ:CRIS
Curis Inc
Revenue
Curis Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Curis Inc
NASDAQ:CRIS
|
Revenue
$10m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-4%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Curis Inc
Revenue Breakdown
Breakdown by Geography
Curis Inc
Breakdown by Segments
Curis Inc
Total Revenue:
10m
USD
|
Gross Royalty Revenue:
9.9m
USD
|
See Also
What is Curis Inc's Revenue?
Revenue
10m
USD
Based on the financial report for Dec 31, 2023, Curis Inc's Revenue amounts to 10m USD.
What is Curis Inc's Revenue growth rate?
Revenue CAGR 10Y
-4%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Curis Inc have been -3% over the past three years , -1% over the past five years , and -4% over the past ten years .